Vaccine for Tick-borne Encephalitis for Adults (TicoVac 0.5ml) and Children (TicoVac 0.25ml)
35.00€
Validity of online orders: 3 months from the date of purchase.
Tick-borne encephalitis (TBE) is a severe natural focal viral disease caused by the tick-borne encephalitis virus (TBEV), affecting the brain, its membranes, or peripheral nerves. TBE is one of the most important viral human central nervous system infections, characterized by residual effects, sometimes leading to disability. TBE is prevalent in many countries worldwide. It was first described in 1927 in Austria, and the TBE virus was isolated in 1937 in the former Soviet Union.
According to ULAC data, the mortality rate from TBE ranges from 0.5% to 4%. About one-third of people who have had TBE do not fully recover. The most common residual effects include inability to concentrate, sleep disorders, persistent headaches, increased sensitivity, and behavioral changes. Less common are pareses (paralysis).
The most effective means of TBE prevention is vaccination. TBE vaccines can be administered to children over 1 year of age. There are two vaccination schedules: regular and accelerated. The first two doses of the regular vaccination schedule are administered at intervals of 1-3 months; the intervals for the third and booster doses may vary depending on the vaccine manufacturer and are specified in the vaccine information leaflet. After full vaccination (3 doses), about 97% of vaccinated individuals develop a protective antibody titer.

